A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation
A Phase 1/2, Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation
Sponsor: Shanghai YingLi Pharmaceutical Co. Ltd.
A PHASE1/PHASE2 clinical study on Advanced Solid Tumor, this trial is ongoing. The trial is conducted by Shanghai YingLi Pharmaceutical Co. Ltd. and has accumulated 4 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
4 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1/PHASE2
Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2024 — Jul 2024 [monthly]
Unknown Status PHASE1_PHASE2
Status: Recruiting → Unknown Status
-
Dec 2021 — Jan 2024 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Nov 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shanghai YingLi Pharmaceutical Co. Ltd.
- Yingli Pharma US, Inc
For direct contact, visit the study record on ClinicalTrials.gov .